{
  "report_rows": [
    {
      "kpi": "JOURNAVX Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$55M vs. cons $49.1M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "ALYFTREK Revenue (Q2 2026)",
      "prediction": "MISS",
      "answer": "pred ~$510M vs. cons $521M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Total Revenue (Q2 2026)",
      "prediction": "IN-LINE",
      "answer": "pred ~$3.22B vs. cons $3.221B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 Revenue (Crinetics raise)",
      "prediction": "BETTER",
      "answer": "guide ~$13.175B midpoint vs. cons $13.053B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY 2026 Non-GAAP EPS (Crinetics opex dilution)",
      "prediction": "LOWER",
      "answer": "guide ~$17.90 midpoint vs. cons $18.23",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "JOURNAVX FY 2026 Revenue (qualitative)",
      "prediction": "BETTER",
      "answer": "guide ~$250M vs. cons $239.8M",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -2.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -4.0,
  "day5_path": "FADE",
  "day5_rationale": "FADE \u2014 sell-side EPS cuts from Crinetics opex raise weigh on the stock over the following days; JOURNAVX beat provides partial offset but does not reverse the EPS dilution narrative",
  "day5_confidence": "MEDIUM"
}